PRAXIS PRECISION MEDICINES, INC. Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value
PRAXIS PRECISION MEDICINES, INC. (PRAX) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value of $187.94 per share for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue · last filed 2026-08-06
- PRAXIS PRECISION MEDICINES, INC. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for the quarter ending 2026-06-30 was $187.94.
- PRAXIS PRECISION MEDICINES, INC. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for the quarter ending 2026-03-31 was $209.19.
- PRAXIS PRECISION MEDICINES, INC. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for the quarter ending 2021-09-30 was $13.45, a 113.49% increase year-over-year.
- PRAXIS PRECISION MEDICINES, INC. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for the quarter ending 2021-06-30 was $16520000.00.
- PRAXIS PRECISION MEDICINES, INC. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2025 was $46.74, a 13.31% increase from fiscal 2024.
- PRAXIS PRECISION MEDICINES, INC. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2024 was $41.25, a 38.75% increase from fiscal 2023.
- PRAXIS PRECISION MEDICINES, INC. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2023 was $29.73.
- PRAXIS PRECISION MEDICINES, INC. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2020 was $2.25, a 65.44% decline from fiscal 2019.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 12 month |
|---|---|---|---|---|
| 2026-06-30 | $187.94 10-Q · filed 2026-08-06 | $207.72 10-Q · filed 2026-08-06 | ||
| 2026-03-31 | $209.19 10-Q · filed 2026-05-07 | |||
| 2025-12-31 | $46.74 10-K · filed 2026-02-19 | |||
| 2024-12-31 | $41.25 10-K · filed 2026-02-19 | |||
| 2023-12-31 | $29.73 10-K · filed 2026-02-19 | |||
| 2021-09-30 | $13.45 10-Q · filed 2021-11-03 | $30.91 10-Q · filed 2021-11-03 | ||
| 2021-06-30 | $16520000.00 10-Q · filed 2021-08-16 | $31.99 10-Q · filed 2021-08-16 | ||
| 2021-03-31 | $37.54 10-Q · filed 2021-05-11 | |||
| 2020-12-31 | $2.25 10-K · filed 2021-03-17 | |||
| 2020-09-30 | $6.30 10-Q · filed 2020-11-23 | $5.41 10-Q · filed 2020-11-23 | ||
| 2019-12-31 | $6.51 10-K · filed 2021-03-17 | |||
| 2019-09-30 | $2.25 10-Q · filed 2020-11-23 | $2.25 10-Q · filed 2020-11-23 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |
| Spyre Therapeutics, Inc. (SYRE) | United States | $7.685B | -43.69 |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |
| Alkermes plc. (ALKS) | $6.844B | 132.74 | |
| RHYTHM PHARMACEUTICALS, INC. (RYTM) | United States | $6.771B | -37.20 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |